This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Clinicaltrials have shown that the vaccine is 90 percent effective in preventing shingles for individuals aged 50 and over. 2) Xevudy (sotrovimab) Xevudy, a monoclonal antibody treatment for SARS-CoV-2, generated £2.31 It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy.
24, 2020 /PRNewswire/ —
COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinicaltrials and it utilizes normal refrigeration (no freezing required) for distribution.
COVAXX is currently conducting a Phase 1 clinicaltrial for the vaccine candidate. .
COVAXX is currently completing a Phase 1 clinicaltrial of UB-612 in Taiwan and will begin Phase 2/3 clinicaltrials in Asia, Latin America and the U.S. This agreement is in addition to the recently announced advanced purchase commitments of more than 140 million doses of COVAXX’s UB-612 vaccine, totaling over $2.8
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Allergies 
98 
Let's personalize your content